A recent study measured mRNA levels of the gene encoding ANRIL in 456 breast carcinomas tissues and found that ANRIL mRNA expression was higher in breast carcinomas tissues than in normal breast tissues, which was exclusively and weakly correlated with ER and PR status and showed a complex association with epithelial–mesenchymal transition markers.[31] We determined ANRIL expression in the plasma of patients with BC and found that its expression was surprisingly higher in patients with TNBC than in patients with NTNBC. Here, CDKN2B-AS1 is linked to breast cancer.